Bar Harbor, Maine — A new study led by MDI Biological Laboratory identifies ML233 as a potent inhibitor of melanin production, offering promise for development of new treatments for pigment-related skin disorders and one melanoma subtype. The compound showed strong effects at low doses in zebrafish, mouse and and human cell models, highlighting potential for dermatological therapies.